Provided by Tiger Fintech (Singapore) Pte. Ltd.

Achilles Therapeutics plc

1.48
+0.0000
Volume:- -
Turnover:- -
Market Cap:60.83M
PE:-0.89
High:1.48
Open:1.48
Low:1.48
Close:1.48
Loading ...

Company Profile

Company Name:
Achilles Therapeutics plc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Directors

Name
Position
Edwin Moses
Chairman of the Board
Iraj Ali
Chief Executive Officer and Director
Carsten Boess
Director
Derek Paul Di Rocco
Director
Martin Murphy
Director
Michael F. Giordano
Director
Roger Rooswinkel
Director

Shareholders

Name
Position
Iraj Ali
Chief Executive Officer and Director
Robert Coutts
Chief Financial Officer
Charles Swanton
Founder
Karl Peggs
Chief Medical Officer and Founder
Mark Lowdell
Founder
Sergio Quezada
Chief Scientific Officer and Founder